Cytel, provider of statistical software and advanced analytics for clinical trial design and execution, has launched East Bayes, an web-based extension of the East platform that enables adoption of the most computationally intensive Bayesian clinical trial designs, without the need for powerful on-site computers.
The launch expands East’s range of Bayesian trial designs by providing a suite of complex Phase I dose-escalation and Phase II dose-finding designs for greater speed, flexibility, and cost-effectiveness in early clinical development. According to Cytel, the East platform facilitated widespread industry adoption of the adaptive clinical trial design and eliminates technological barriers to greater Bayesian clinical trial design adoption, providing the pharmaceutical industry with the tools needed for more clinical trial success.
East Bayes expands East Alloy’s functionality and computing power and integrates a selection of trial designs from Laiya Consulting’s U-Design software. Through the new platform, Cytel says customers will receive quick, easy access to a growing selection of advanced and innovative early-phase Bayesian dose-finding designs, all through a simple and intuitive graphical user interface. Designs will allow clinicians the ability to identify optimal dosing more efficiently, improve patient safety, and shorten clinical trials.
Yannis Jemiai, Chief Scientific Officer at Cytel, said: “East Bayes brings these complex mathematical models and algorithms smoothly and rapidly to clinicians in an accessible way, so now they can reap the benefits of Bayesian innovation confidently and autonomously.”